N/A N=12 Investigation of a Novel Sleep Surface for Treatment of Positional Sleep Apnea
Sleep Apnea, Obstructive
Primary: Apnea-hypopnea Index (AHI)- Intention to Treat Analysis — 9.8; 12.6 events/hr
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=1,519 Efficacy and Safety of Tolvaptan in Subjects With Chronic Kidney Disease Between Late Stage 2 to Early Stage 4 Due to Autosomal Dominant Polycystic Kidney Disease
Chronic Kidney Disease · Autosomal Dominant Polycystic Kidney Disease
Primary: The Mean Annualized Change in eGFR From Pretreatment Baseline to Post-treatment Follow-up. — -2.339; -3.610 mL/min/1.73 m^2/year — p=<0.0001
Phase 2 N=23 Combination Chemotherapy in Treating Patients With Neurofibromatosis and Progressive Plexiform Neurofibromas
Neurofibromatosis Type 1 · Precancerous Condition
Primary: Time to Disease Progression — 25.8; 29.2; 25.8 Months
Phase 4 N=60 Novartis Everolimus Transition
Graft Dysfunction · Interstitial Fibrosis
Primary: Kidney Allograft Fibrosis Assessment — 22.9; 20.8; 22.9; 27.8 % of fibrosis
Phase 3 N=120 A Study to Evaluate the Efficacy of Investigational OTC Eye Drops
Ophthalmic Solutions
Primary: Clinician Assessment of Change From Baseline in Redness at 60 Seconds After First Product Application — 0.31; 0.27; 0.32 units on a scale — p=0.392
Phase 2 N=25 A Study of Neoadjuvant FOLFIRINOX and FDR-Gemcitabine With Concurrent IMRT in Patients
Pancreatic Cancer
Primary: The Percentage of Patients That Underwent an R0 Resection — 52 percentage of patients
Phase 3 N=464 Open-label Study to Evaluate the Effectiveness of an Intramuscular Formulation of Aripiprazole (OPC-14597) as Maintenance Treatment in Patients With Bipolar I Disorder
Bipolar I
Primary: Number of Participants With Adverse Events — 374; 374; 30; 41 Participants
Phase 2 N=204 Study of Gemcitabine, Abraxane® Plus Placebo Versus Gemcitabine, Abraxane® Plus 1 or 2 Truncated Courses of Demcizumab in Subjects With 1st-Line Metastatic Pancreatic Ductal Adenocarcinoma
Pancreatic Cancer
Primary: Hazard of Progression in the Placebo/Placebo Arm and the Pooled Demcizumab Arms — 38; 70; 5; 12 Participants — p==0.7158
N/A N=122 Interdisciplinary and Family Intervention to Prevent Type 2 Diabetes
Prediabetes
Primary: Individual Insulin Resistance and Insulin Secretion — 4.9; 4.8 score on a scale — p=0.844
Phase 2 N=96 Study of Thyrotropin-Releasing Hormone in Normal Volunteers and in Patients With Thyroid or Pituitary Abnormalities
Healthy · Pituitary Disease · Thyroid Disease
Primary: TSH Response to TRH — 11.47 mcIU/mL
Phase 2 N=67 Imatinib Treatment in Recent Onset Type 1 Diabetes Mellitus
Diabetes Mellitus, Type I · Diabetes Mellitus, Insulin-Dependent, 1 · Type 1 Diabetes Mellitus
Primary: Area Under the Stimulated C-peptide Curve (AUC) Mean Over the First 2 Hours of a 4 Hour Mixed Meal Tolerance Test at the 1 Year Visit — 0.834; 0.775 nmol/L — p=0.048
Phase 3 N=314 OPTIMA: Efficacy of Optimized Re-treatment and Step-up Therapy With Omalizumab in Chronic Spontaneous Urticaria (CSU) Patients
Chronic Spontaneous Urticaria
Primary: Number of Participants Who Were Clinically Well-controlled (UAS7<=6) After the Initial Dosing Period, Relapsed (UAS7>=16) When Treatment Was Discontinued, and Who…
Phase 3 N=320 Study to Evaluate the Overall Performance of the Zalviso System™ (Sufentanil Sublingual Tablet System) 15 mcg
Moderate-to-severe Acute Pain
Primary: Percentage of Patients Who Experienced at Least One System-generated Error Based on the Controller Data While Using the Zalviso System — 2.2 percentage of patients
Phase 3 N=817 TP05 for the Treatment of Mild to Moderate Active Ulcerative Colitis (UC)
Acute Ulcerative Colitis
Primary: Period 1: Clinical and Endoscopic Remission — 87; 95 Participants — p=0.005
Phase 2 N=46 Study of Lenalidomide and Ofatumumab for the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma
Non-Hodgkin's Lymphoma
Primary: Phase I: Maximum Tolerated Dose (MTD) of Lenalidomide — 10 milligrams